| Name | Title | Contact Details |
|---|---|---|
Arnaud Lesegretain |
VP Oncology R&D - Head of Oncology Alpha Portfolio | Profile |
Siddhartha Rawat |
Associate Director, Clinical Development, Global Onclogy R&D | Profile |
John Toso |
Executive Director, Global Head, Translational Development, Oncology R&D | Profile |
Hayes Williams |
Head of Data Governance, R&D | Profile |
Robert McLeod |
Senior Director Clinical Development, Global Oncology R&D | Profile |
Integrated DNA Technologies, Inc. (IDT) develops, manufactures, and markets nucleic acid products for the life sciences industry in the areas of academic research, biotechnology, agriculture, medical diagnostics, and pharmaceutical development. The company`s primary business is the production of custom oligonucleotides for molecular biology applications. IDT has developed proprietary technologies for genomics applications such as next generation sequencing, CRISPR genome editing, qPCR, and RNA interference. Through its GMP services, IDT manufactures products used in diagnostic tests for many forms of cancer and most inherited and infectious diseases. The company serves its customers through direct sales in many countries and a network of international distributors. IDT has its manufacturing headquarters in Coralville, Iowa, USA, with additional manufacturing facilities in San Diego, California, USA; Leuven, Belgium; and Singapore. The company has offices in Skokie, Illinois, USA; Glasgow, United Kingdom; Munich, Germany; and Baulkham Hills, Australia.
Biothera, the Immune Health Company is a Saint Paul, MN-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
MindMaze is pioneering a breakthrough computing platform that captures brain activity upon intent, creating a new operating system for computers - a brain O/S - with initial applications in the healthcare and gaming industries.
#Cereset is a wellness company that helps their clients relax their #brain to manage stress and achieve restful #sleep. 🧠💤 Centers across the US & Europe.
Palleon is targeting glycan-sensing checkpoints to unleash both the innate and adaptive immune responses to cancer.